Product Name

Ledipasvir

Name: Ledipasvir - LGM Pharma
SKU: 1256388-51-8

CAS Number

1256388-51-8

LGM Pharma is an API distributor. LGM Pharma can supply CGMP and/or DMF products, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, pharmacies, or any pharmaceutical companies.

Questions? Call our customer API support number 1-(800)-881-8210

Product Name:

Ledipasvir

CAS Number:

1256388-51-8

Indication:

Ledipasvir is an indicated for the treatment of chronic hepatitis C genotype 1 infection, in conjunction with Sofosbuvir.

Mode of Action:

Mutations that confer resistance to Ledipasvir in Hepatitis C Virus replicon cells, which are found in NS5A, infer that NS5A is the direct target of Ledipasvir.

Pharmacodynamics:

Ledipasvir is a novel Hepatitis C Virus NS5A inhibitor that is best administered adjunctively with other antiviral drugs, leading to very successful results. A cure rate of up to 100 percent is possible when Ledipasvir is used in the correct combinations of drug cocktails. By effectively inhibiting the viral phosphoprotein NS5A Ledipasvir aids in controlling viral assembly, replication and secretion.

Metabolism:

Ledipasvir is primarily eliminated in the feces, with a renal excretion being considered as a minor elimination pathway. Whole blood and plasma levels of Ledipasvir are undetectable at both 36 and 48 hours post dosage.

Toxicity:

Reports that Ledipasvir, when used in combination with Sofosbuvir and Tenofovir may increase Tenofovir levels in the body. While severe toxicity has not been documented a concern regarding co-administration of Tenofovir with Ledipasvir may lead to renal toxicity. The majority of adverse effects reported are not severe and include fatigue, nausea, dizziness and diarrhea.

PubChem:

67505836

Formula:

C49-H54-F2-N8-O6

Molecular Mass:

889.0116

Synonyms:

GS 5885, GS-5885, GS5885, Ledipasvir, UNII-013TE6E4WV, WHO 9796

SMILES:

CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1c3[nH]c(cn3)c4ccc-5c(c4)C(c6c5ccc(c6)c7ccc8c(c7)[nH]c(n8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)(F)F)NC(=O)OC

General Reference:

PLoS One. 2015 Apr 9;10(4):e0122844. doi: 10.1371/journal.pone.0122844. eCollection 2015.
Infect Drug Resist. 2014 Mar 5;7:41-56. doi: 10.2147/IDR.S36247. eCollection 2014.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.

Questions? Call our customer API support number 1-(800)-881-8210.

Ask us about this product

API’s From Quality Manufacturers:

Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
Premium quality GMP certified and fully accredited API manufacturing plants
Technical packages as well as access to filed DMF, ASMF or CEP (subject to availability)
Regulatory and technical assistance towards any submission type based on specific customer requirements

Ledipasvir

1256388-51-8

Ask us about this product

API’s From Quality Manufacturers:

Find an API Product